Tiziana Life Sciences Ltd (TLSA)

$1.46 +0.02 (1.39%)
Market Cap 179.47M
Revenue (ttm) 0.00
Net Income (ttm) -11.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 208,500
Avg Vol 350,942
Day's Range N/A - N/A
Shares Out 118.85M
Stochastic %K 14%
Beta 0.02
Analysts Strong Sell
Price Target $8.00

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 7495 2379
Address:
14/15 Conduit Street, London, United Kingdom
SallyC
SallyC Feb. 4 at 8:30 AM
$TLSA Get ready folks, this one is going to POP!!
0 · Reply
HopehelpsU
HopehelpsU Feb. 4 at 12:40 AM
$TLSA Partial shutdown is over.... FDA back to full staff. ODD now within 20-40 days imo.... $3-$4 coming. It qill be a apike, probably settle around mid 2s... Stay alert ⚠️!
0 · Reply
EderT
EderT Feb. 3 at 11:05 PM
$QQQ $PLTR $TLSA $MSTR mothers ahead of the collapse my bot was already building short positions in MSTR SCAM Saylor is going to get liquidated
0 · Reply
IHOPEIWINBRO
IHOPEIWINBRO Feb. 3 at 7:23 PM
$UBER 10 p/e lolol whos sold to me undr 77.50 tell me please... stop chasing $PLTR at 300 p/e or $TLSA at 200 p/e nut cases
0 · Reply
Housatonic1864
Housatonic1864 Feb. 3 at 2:48 PM
$TLSA bought another $4,000 worth. Giddy up🏴‍☠️
0 · Reply
ThinkYouCan
ThinkYouCan Jan. 31 at 10:29 PM
$DJT $SPY $TLSA $NVDA $BTC.X Did Ratner get blackmailed into directing the Melania movie? What depravity is this admin protecting for blackmail purposes?
1 · Reply
Waterwing
Waterwing Jan. 31 at 7:13 PM
$TLSA
0 · Reply
Laurensian11
Laurensian11 Jan. 30 at 8:02 PM
$TLSA It’s been so soon since the CEO bought $3,000,000 of shares (holding approx $450,000 before that). Plus he has a warrant to add another $3,600,000. Words and figures speak volumes
0 · Reply
rp6577
rp6577 Jan. 30 at 5:55 PM
$TLSA I find it odd that the share price is not catching a bid. We have MS data round the corner and are now fully funded. Seems like a perfect time to buy in my view $XBI
1 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Jan. 30 at 5:35 PM
$TLSA if you gamble on a GC company. expect to lose it all! never trust GC!
3 · Reply
Latest News on TLSA
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Jan 20, 2026, 11:15 AM EST - 14 days ago

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Jan 16, 2026, 2:45 PM EST - 18 days ago

Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Jan 16, 2026, 7:00 AM EST - 18 days ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Jan 9, 2026, 7:00 AM EST - 25 days ago

Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Dec 29, 2025, 8:00 AM EST - 5 weeks ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Dec 19, 2025, 11:00 AM EST - 6 weeks ago

Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Dec 17, 2025, 10:00 AM EST - 6 weeks ago

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Dec 17, 2025, 8:45 AM EST - 6 weeks ago

Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Dec 15, 2025, 3:07 PM EST - 7 weeks ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Dec 15, 2025, 7:30 AM EST - 7 weeks ago

Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Dec 12, 2025, 2:10 PM EST - 7 weeks ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Dec 2, 2025, 7:00 AM EST - 2 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Nov 25, 2025, 8:30 AM EST - 2 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 2 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot

Oct 31, 2025, 9:43 AM EDT - 3 months ago

Tiziana Life Sciences: Foralumab's Intranasal Push Is A Good Moonshot

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Oct 29, 2025, 7:00 AM EDT - 3 months ago

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Sep 30, 2025, 8:30 AM EDT - 4 months ago

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Sep 24, 2025, 8:30 AM EDT - 4 months ago

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Sep 15, 2025, 8:00 AM EDT - 5 months ago

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Sep 5, 2025, 8:30 AM EDT - 5 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Aug 14, 2025, 8:30 AM EDT - 6 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Aug 11, 2025, 9:00 AM EDT - 6 months ago

FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Jul 21, 2025, 7:00 AM EDT - 7 months ago

Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Jun 13, 2025, 11:08 PM EDT - 8 months ago

Tiziana: Scope Of Foralumab Goes Beyond That Of Multiple Sclerosis Targeting

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Jun 13, 2025, 10:30 AM EDT - 8 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

Tiziana Life Sciences to Present at the Bio International Convention

Jun 13, 2025, 8:30 AM EDT - 8 months ago

Tiziana Life Sciences to Present at the Bio International Convention

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025, 7:00 AM EDT - 9 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025, 8:00 AM EDT - 9 months ago

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana's Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025, 7:00 AM EDT - 9 months ago

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025, 7:00 AM EDT - 9 months ago

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Apr 23, 2025, 7:00 AM EDT - 10 months ago

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Mar 25, 2025, 8:00 AM EDT - 11 months ago

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Mar 17, 2025, 8:00 AM EDT - 11 months ago

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Mar 14, 2025, 8:30 AM EDT - 11 months ago

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Mar 4, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Feb 27, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Feb 25, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Feb 21, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Feb 18, 2025, 8:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Feb 11, 2025, 9:15 AM EST - 1 year ago

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Jan 23, 2025, 3:00 PM EST - 1 year ago

Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Jan 23, 2025, 8:54 AM EST - 1 year ago

Tiziana Life Sciences not to engage in capital raising activities for the immediate future

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Jan 22, 2025, 4:05 PM EST - 1 year ago

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Jan 8, 2025, 7:00 AM EST - 1 year ago

Tiziana Life Sciences Announces Review Article Published in Nature Highlighting Foralumab's Potential in the Treatment of Neurological Disease

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Nov 1, 2024, 1:00 PM EDT - 1 year ago

Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Oct 30, 2024, 10:29 PM EDT - 1 year ago

Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $10 Million

Tiziana Life Sciences Appoints New Chief Executive Officer

Aug 19, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Appoints New Chief Executive Officer

Tiziana Life Sciences Granted FDA Fast Track Designation

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Tiziana Life Sciences Granted FDA Fast Track Designation

Tiziana Receives $3.4 Million in Non-Dilutive Funding

Jun 28, 2024, 11:01 AM EDT - 1 year ago

Tiziana Receives $3.4 Million in Non-Dilutive Funding

SallyC
SallyC Feb. 4 at 8:30 AM
$TLSA Get ready folks, this one is going to POP!!
0 · Reply
HopehelpsU
HopehelpsU Feb. 4 at 12:40 AM
$TLSA Partial shutdown is over.... FDA back to full staff. ODD now within 20-40 days imo.... $3-$4 coming. It qill be a apike, probably settle around mid 2s... Stay alert ⚠️!
0 · Reply
EderT
EderT Feb. 3 at 11:05 PM
$QQQ $PLTR $TLSA $MSTR mothers ahead of the collapse my bot was already building short positions in MSTR SCAM Saylor is going to get liquidated
0 · Reply
IHOPEIWINBRO
IHOPEIWINBRO Feb. 3 at 7:23 PM
$UBER 10 p/e lolol whos sold to me undr 77.50 tell me please... stop chasing $PLTR at 300 p/e or $TLSA at 200 p/e nut cases
0 · Reply
Housatonic1864
Housatonic1864 Feb. 3 at 2:48 PM
$TLSA bought another $4,000 worth. Giddy up🏴‍☠️
0 · Reply
ThinkYouCan
ThinkYouCan Jan. 31 at 10:29 PM
$DJT $SPY $TLSA $NVDA $BTC.X Did Ratner get blackmailed into directing the Melania movie? What depravity is this admin protecting for blackmail purposes?
1 · Reply
Waterwing
Waterwing Jan. 31 at 7:13 PM
$TLSA
0 · Reply
Laurensian11
Laurensian11 Jan. 30 at 8:02 PM
$TLSA It’s been so soon since the CEO bought $3,000,000 of shares (holding approx $450,000 before that). Plus he has a warrant to add another $3,600,000. Words and figures speak volumes
0 · Reply
rp6577
rp6577 Jan. 30 at 5:55 PM
$TLSA I find it odd that the share price is not catching a bid. We have MS data round the corner and are now fully funded. Seems like a perfect time to buy in my view $XBI
1 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Jan. 30 at 5:35 PM
$TLSA if you gamble on a GC company. expect to lose it all! never trust GC!
3 · Reply
AlphaTrader8
AlphaTrader8 Jan. 30 at 5:16 PM
$SLV Going Down Another $13.00+ Down $GLD $SPY $QQQ $TLSA
0 · Reply
Merlintrader
Merlintrader Jan. 30 at 1:02 PM
$TLSA https://www.merlintrader.com/tlsa-tiziana-life-sciences-ltd/ When management and insiders hold roughly 36% of the equity and are clearly putting their own capital at risk, it is reasonable to grant them at least some trust that their objectives are aligned with those of other shareholders, even though this does not guarantee any future outcome, but I like that a lot. I’ve put together a summary of the situation if you guys feel like reading it
0 · Reply
rispi
rispi Jan. 30 at 10:32 AM
@Merlintrader hi, I'm considering investing in $FBIO $RCKT $TLSA $KYTX Have you already published any DD about one of those? Right now I don't have any open position yet. thanks
3 · Reply
Game_Day
Game_Day Jan. 29 at 10:20 PM
$TLSA oy vey
0 · Reply
rp6577
rp6577 Jan. 29 at 2:47 PM
$TLSA SPMS data first half of 2026. That will be a huge milestone for the company. That will then be followed by the MSA data
0 · Reply
23ChaseColeman23
23ChaseColeman23 Jan. 29 at 4:22 AM
Love that $TLSA sits inside of $BULZ $FNGU dumped it in 2024 for $CRWD or $NOW 🤭 🤭
0 · Reply
HopehelpsU
HopehelpsU Jan. 28 at 7:54 PM
$TLSA Sadly...the facking 🤡 s on both sides of the aisle in Washington will probably shut down the government on Friday. This affects the timing of the ODD review by the length of the shutdown at a minimum. 🙏 🤲....... EXTREMELY FACKIN
0 · Reply
HopehelpsU
HopehelpsU Jan. 28 at 5:26 PM
$TLSA ADDED...... ODD within 20-50 days imo...
0 · Reply
upsoon007
upsoon007 Jan. 28 at 10:16 AM
$TLSA what would the purpose of recent substantial insider buys (not only by GC but also CEO) have been then? The scenario you describe doesn‘t seem to make sense here.
2 · Reply
WHATABOUTSTOCKS
WHATABOUTSTOCKS Jan. 28 at 9:11 AM
$TLSA agreed. don’t trust GC. gamble for me - high risk high reward.
0 · Reply
Discernment
Discernment Jan. 27 at 9:55 PM
$TLSA Retracted offering because the market knows what a group of thieves Cerrone and friends are. Beware they don't "sell" the drug to Cerrone's offshore shell company for zero dollars and some worthless CVR's, just like this group did over at Hepion Pharmaceuticals. These people all sit on the boards of various companies, colluding to rip off investors.
4 · Reply
chris333
chris333 Jan. 27 at 7:52 PM
$MVIS With the takeover of some Luminar assets, $TLSA uses now Microvision lidar units.
1 · Reply